secwatch.observer — SEC 8-K summary
======================================

Issuer:     FATE THERAPEUTICS INC (FATE)
CIK:        0001434316
Form:       8-K
Filed at:   2024-11-12T23:59:59+00:00
Accession:  0000950170-24-125307
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fate Therapeutics Q3 rev $3.1M, cash $330.5M; FT819/FT522/FT825 clinical progress
--------------------------------------------------------------------------------

- Q3 revenue of $3.1M from Ono collaboration; total op expense $55.5M incl $11.8M stock comp.
- Cash, equivalents & investments $330.5M; projected operating runway through end of 2026.
- FT819 Phase 1 SLE: 3 patients dosed with fludarabine-free conditioning; no DLTs/CRS/ICANS/GvHD; data at ACR and ASH.
- FT522 IND allowed for B cell-mediated autoimmune basket study; initial BCL clinical data at ACR Convergence.
- FT825/ONO-8250 initial solid tumor data: safety profile favorable, CAR T expansion with activated phenotype at 100M dose.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1434316/000095017024125307/0000950170-24-125307-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1434316/000095017024125307/fate-20241112.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-125307

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer